(ANSA) - ROME, MARCH 04 - The first long-acting monoclonal antibody designed to protect all newborns for the entire season from respiratory syncytial virus (RSV) proves its efficacy.
To say it is a study published in the New England Journal of Medicine.
Nirsevimab (this is the name of the monoclonal, developed by Sanofi and Astrazeneca) achieved the goal of the study by reducing the incidence, compared to placebo, of medical assistance needed for lower respiratory tract infections caused by this virus by 74.5%. comebronchiolitis and pneumonia.
"The RSV has seen a resurgence following the easing of public health measures from Covid-19 - explains William Muller, researcher who led the work - This demonstrates how much a broad immunization approach is needed to help mitigate the substantial global burden that RSV imposes on newborns, their families and health services.
These exciting data show that nirsevimab has the potential to offer protection to all newborns, which would be a paradigm shift in the approach to this disease. "
The presentation of the registration dossiers is expected for the first half of 2022. (ANSA).
